Trial Profile
Exploring the Impact of de Novo Everolimus on Key Determinants of Long Term Outcome After Kidney Transplantation: NODAT, Viral Infection, DSA, Proteinuria and Graft Histology
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolic acid; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms ADVISE
- Sponsors Novartis Pharmaceuticals
- 20 Feb 2018 Status changed from recruiting to completed.
- 14 Nov 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 14 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2017.